Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sebetralstat SCHEMBL17785421 | 1.00 | KLKB1 (1.00) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Sebetralstat SCHEMBL22495449 | 0.99 | KLKB1 (0.98) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Sebetralstat SCHEMBL28770013 | 0.99 | KLKB1 (0.98) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Sebetralstat SCHEMBL22495443 | 0.98 | KLKB1 (0.95) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Sebetralstat SCHEMBL22495486 | 0.97 | KLKB1 (0.94) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Sebetralstat SCHEMBL22495499 | 0.97 | KLKB1 (0.94) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Sebetralstat SCHEMBL19668181 | 0.95 | KLKB1 (0.90) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Sebetralstat SCHEMBL28769406 | 0.94 | KLKB1 (0.88) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| Sebetralstat SCHEMBL19668205 | 0.94 | KLKB1 (0.88) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL21145544 | 0.93 | KLKB1 (1.00) | KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281397-A1 | FORMULATIONS OF A PLASMA KALLIKREIN INHIBITOR | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2025-09-11 | — | — | US | claimed |
| EP-4480545-A2 | FORMULATIONS OF A PLASMA KALLIKREIN INHIBITOR | Kalvista Pharmaceuticals Limited (GB) | 2024-12-25 | — | — | EP | claimed |
| CN-119095589-A | Formulations of plasma kallikrein inhibitors | 卡尔维斯塔制药有限公司 | 2024-12-06 | — | — | CN | claimed |
| EP-4288036-B1 | FORMULATIONS OF A PLASMA KALLIKREIN INHIBITOR | KALVISTA PHARMACEUTICALS LTD (GB) | 2024-08-07 | — | — | EP | claimed |
| EP-4288036-A1 | FORMULATIONS OF A PLASMA KALLIKREIN INHIBITOR | Kalvista Pharmaceuticals Limited (GB) | 2023-12-13 | — | — | EP | claimed |
| WO-2023209381-A1 | FORMULATIONS OF A PLASMA KALLIKREIN INHIBITOR | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-11-02 | — | — | WO | claimed |
| WO-2023002219-A1 | TREATMENTS OF HEREDITARY ANGIOEDEMA | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-01-26 | — | — | WO | claimed |
| EP-4737450-A1 | HETEROAROMATIC FORMAMIDE COMPOUNDS AND USES THEREOF IN MEDICINE | Longwood Pharmaceuticals (Hangzhou) Co., Ltd (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-20260048008-A1 | ORGANOGELS FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF | OCULAR THERAPEUTIX INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4695324-A1 | BIO-ORTHOGONAL HYDROGELS FOR SUSTAINED RELEASE DRUG DELIVERY | Ocular Therapeutix, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4683964-A2 | POLY(ETHYLENE GLYCOL) BASED DENDRIMER-LIKE HYPERBRANCHED MACROMOLECULES, METHODS OF PREPARATION AND USE THEREOF | Ocular Therapeutix, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4673437-A1 | NEW SOLID FORM OF A PLASMA KALLIKREIN INHIBITOR | Kalvista Pharmaceuticals Limited (GB) | 2026-01-07 | — | — | EP | disclosed |
| WO-2026003532-A1 | SEBETRALSTAT FOR THE TREATMENT OF ANXIETY ASSOCIATED WITH HEREDITARY ANGIOEDEMA | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2026-01-02 | — | — | WO | disclosed |
| WO-2024035690-A1 | ORGANOGELS FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF | OCULAR THERAPEUTIX, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| EP-4288036-A1 | FORMULATIONS OF A PLASMA KALLIKREIN INHIBITOR | Kalvista Pharmaceuticals Limited (GB) | 2023-12-13 | — | — | EP | disclosed |
| US-20230381162-A1 | TREATMENTS OF ANGIOEDEMA | DRI UK LP (KY) | 2023-11-30 | — | — | US | disclosed |
| WO-2023209381-A1 | FORMULATIONS OF A PLASMA KALLIKREIN INHIBITOR | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-11-02 | — | — | WO | disclosed |
| CN-116003386-A | Deuterated N-benzyl pyridone pyrazole carboxamides, pharmaceutical composition and application | 药康众拓(北京)医药科技有限公司 | 2023-04-25 | — | — | CN | disclosed |
| WO-2023002219-A1 | TREATMENTS OF HEREDITARY ANGIOEDEMA | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-01-26 | — | — | WO | disclosed |
| WO-2022079446-A1 | TREATMENTS OF ANGIOEDEMA | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048008-A1 | ORGANOGELS FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF | KIT, IL33, LY96 | KLKB1 500/4885CYP3A4 42/4885CYP2C8 38/4885 |
| US-20250281397-A1 | FORMULATIONS OF A PLASMA KALLIKREIN INHIBITOR | KLKB1, KLK5, KLK1 | KLKB1 1/4885CYP3A4 412/4885CYP2C8 1179/4885 |
| US-20230381162-A1 | TREATMENTS OF ANGIOEDEMA | BDKRB2, KLKB1, BDKRB1 | KLKB1 2/4885CYP3A4 1024/4885CYP2C8 2278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.